Embecta (NASDAQ:EMBC – Get Free Report) issued an update on its FY24 earnings guidance on Friday morning. The company provided earnings per share guidance of $2.30-2.35 for the period, compared to the consensus earnings per share estimate of $2.28. The company issued revenue guidance of $1.111-1.116 billion, compared to the consensus revenue estimate of $1.11 billion. Embecta also updated its FY 2024 guidance to 2.300-2.350 EPS.
Wall Street Analysts Forecast Growth
Separately, Morgan Stanley cut their price target on Embecta from $13.00 to $12.00 and set an underweight rating for the company in a report on Monday, July 15th.
View Our Latest Research Report on EMBC
Embecta Trading Up 7.3 %
Embecta (NASDAQ:EMBC – Get Free Report) last issued its earnings results on Friday, August 9th. The company reported $0.74 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.26. Embecta had a net margin of 6.20% and a negative return on equity of 18.42%. The business had revenue of $272.50 million for the quarter, compared to the consensus estimate of $267.44 million. During the same period in the prior year, the firm earned $0.69 EPS. The company’s revenue for the quarter was down 4.8% compared to the same quarter last year. Analysts predict that Embecta will post 2.29 earnings per share for the current fiscal year.
Embecta Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, September 13th. Stockholders of record on Tuesday, August 27th will be issued a $0.15 dividend. The ex-dividend date is Tuesday, August 27th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 3.90%. Embecta’s dividend payout ratio is presently 49.59%.
About Embecta
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Further Reading
- Five stocks we like better than Embecta
- Conference Calls and Individual Investors
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- What Investors Need to Know to Beat the Market
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- MarketBeat Week in Review – 8/5 – 8/9
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.